OnKure Therapeutics Inc. (OKUR)

Discovering and developing the next generation of oncology precision medicines. Visit the OnKure Website

The University of Colorado Connection

OnKure Therapeutics

OnKure Therapeutics is a publicly traded, Boulder-based clinical-stage biopharmaceutical company focused on developing best-in-class precision medicines for cancer. Its lead program, OKI-219, is a selective PI3KαH1047R inhibitor currently in clinical trials, with additional programs in development targeting other oncogenic mutations within the PI3K pathway. OnKure was co-founded by Xuedong Liu  (CU Boulder Biochemistry), and its origins are closely connected to CU-based research. Liu continues his innovation at CU with additional startups and preclinical assets in development.

Funding Status and Investment Opportunities

  • Industry Applications: Health and Wellness, Biotech​, Therapeutics
  • Funding Stage: Publicly traded—OKUR

In the News

More Startups News

Venture Partners Programs​

Path to Commercialization

Technology Development Funding

U.S. National Institutes of Health

U.S. National Institutes of Health (NIH)

    This page was last updated on April 3, 2025. Please email vpnews@colorado.edu for corrections or updates

The Insider Investor E-Newsletter

The Insider is Venture Partners at CU Boulder's monthly newsletter featuring the latest headlines, news, events, opportunities and emerging innovations from the university. We have several editions for our audiences.

Subscribe to The Insider  

Questions about investment opportunities?

Amy Dodenhoff

Amy Dodenhoff · Director of Venture Development

Contact Amy 

Media Inquiries

For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.

For media inquiries, please visit colorado.edu/news/formedia.